Get notified when it's back:
Research & Education
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist originally developed by Eli Lilly. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Tirzepatide simultaneously activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing superior weight loss and glycemic control compared to GLP-1 receptor agonists alone. In the SURMOUNT clinical trials, tirzepatide produced average weight loss of 20-26% of body weight at the highest dose, making it the most effective non-surgical weight loss intervention ever studied.
No reviews yet. Be the first to review this product!